Prevention committee

Prevention committee

ESGO Prevention 2

The Prevention Committee was established in 2019 to fulfil the ESGO vision: Best treatment and prevention in gynaecological cancer. ESGO has set as its mission to improve the health and well-being of women with gynaecological cancers through prevention, research, excellence in care and education. The Prevention Committee is therefore one of the cornerstones to ensure the fulfilment of its mission.

The Chair of the Prevention Committee is Prof. Murat Gultekin.

Committee Goals

  • Facilitate systematic research, issue scientific publications, and disseminate findings in the prevention and treatment of pre-invasive diseases.
  • Raise public and governmental awareness and advocate about gynaecological cancers, their prevention and treatment through ENGAGe.
  • Collaborate with professional societies, patient advocacy organisations, policymakers and other stakeholders to advance gynaecological cancers prevention and care.
  • Contribute to cervical cancer elimination in Europe in line with the WHO elimination programme 2030. Decrease mortality and extend life of gynaecological cancer patients in line with the EU Beat the cancer plan.

Committee Structure

 Prevention Committee Chair: Murat Gultekin








Marc Arbyn, Esat Bilal, Nicolo Bizzarri, Sarah Bowden, Laia Bruni, Laura Burney Ellis, Kim Chatzistamatiou, Volkan Ege, Houssein El Hajj, Omar Gassama, Livia Giordano, Mihaela Grigore, Reda Hemida, Elmar Joura, Joana Kacperczyk-Bartnik, Vesna Kesic, Maria Kyrgiou, Belen Lopez, Anita Mitra, Nagham Ibraheem Mahdi, Afraa Mahjoob Al-Naddawi, Eva-Maria Niine-Roolaht, Patrick Petignat, Alejandra Picconi, Mario Preti, Zoia Razumova, Jalid Sehouli, Aleksandra Shavrova, Nadja Taumberger, Charalampos Theofanakis, Icó Tóth, Andreas Ullrich, Alexandra Wagner, Ignacio Zapardiel

Prevention Committee webinars in 2024

We are preparing three webinars for you, save the date to your calendar!


Ovarian cancer prevention - 28th February 2024, 7-8:30 pm CET

Click here to register for free.

Ovarian cancers are among the most common gynaecological cancers among females. Despite the advances in treatment, the survival rates are still far away from our expectations. On the other hand, there is important scientific evidence accumulated in both carcinogenesis and the genetical background of these cancers and there is now a possibility to prevent these cancers using genetic screening, defining the risk of lifetime cancer development, and using either chemical or surgical prophylaxis to those high-risk populations. This webinar will summarize the existing evidence from the most well-known European experts.


Prof. Ranjit Manchanda (UK)

  • Ovarian cancer precision prevention: improving ascertainment and personalised surgical approaches: This presentation will address the strides towards improving precision prevention of ovarian cancer through improving ascertainment of individuals at increased risk, as well as refining targeted surgical prevention strategies including broadening access for surgical prevention, and personalisation of the cancer susceptibility gene and risk specific age/timing of surgery and impact on cancers prevented.

Dr. Claudia Marchetti (Italy)

  • Oral contraceptives, hormonal IUDs, and chemo prevention: Increasing numbers of BRCA ½ mutated patients are being identified in the current times. In these women, data about the effects and safety of contraception on cancer risks are lacking, as well as international guidelines. On the other side, oral contraceptives have been the most widely studied chemo-preventive agents in ovarian cancer. However, still, now, the achievement of optimal chemoprevention against ovarian cancer remains an unmet need. Moreover, other non-hormonal chemo-preventive agents have also been proposed (Aspirin, NSAID, PARPi).
    In this webinar, we’ll try to clarify the issue of oral contraception for BRCA carriers with an insight into the currently available recommendations. We will also deepen the current panorama and prospects of medical prevention for OC in this setting of patients.

Dr. Eric Leblanc (France)

  • Surgical prophylaxis: RRSO (impact – OC-risk/OC-mortality/BC-risk; protocol; SEEFIM), need for HRT, Radical Fimbriectomy, Risk-reducing early salpingectomy and Delayed oophorectomy



Prof. Murat Gultekin (Turkey)

Prof. Maria Kyrgiou (UK)


This webinar is offered to you for free within the commitment of ESGO Prevention to provide premium educational contact. All you have to do is register here.



HPV prevention in pregnancy - 9th May 2024

Speakers will be defined soon, you may already register here.


Endometrial cancer prevention - 9th October 2024

Speakers will be defined soon, you may already register here.


All Prevention Committee webinars are available on the eAcademy portal

Click on the link to see them all.

Committee Publications

Publications 2024
  • Genital tract microbiota composition profiles and use of prebiotics and probiotics in gynaecological cancer prevention: review of the current evidence, the European Society of Gynaecological Oncology prevention committee statement, The European Society of Gynaecological Oncology (ESGO) Prevention Committee Statement. M. Kyrgiou, December 2023, published in Lancet Microbe
Publications 2023
Publications 2021
Publications 2020
Publications 2019

Cooperation with key stakeholders


World Health Organization has launched ''Cervical Cancer Elimination Program'' on November 19, 2020.

The program asks the countries to vaccinate the girls under 15 years of age (90% coverage), to screen females by minimal two times when they are 35 and 45 (70%) coverage and to treat the lesions detected appropriately (in 90% of cases).

Modelling studies show that if all countries can implement the program until 2030 and can achieve these targets, there will be a 30% reduction in cervical cancer mortality by 2030 and the cervical cancer may be eliminated until the end of this century (namely incidence less than 4 \ 100.000).


ESGO Prevention committee has joined in to fulfil the WHO cervical cancer elimination strategy as a leading European actor in prevention.

European projects

RISCC: Risk-based Screening for Cervical Cancer

ESGO/ENGAGe is involved in the Horizon 2020 RISCC project.

Within the RISCC project ESGO / ENGAGe is responsible for the co-creation of the e-health/m-health platform for risk based cervical cancer screening and for the dissemination of the results to 12 ENGAGe member countries. This project is planned for five years and intended to terminate in 2025.

For more information about the ESGO/ENGAGe involvement please use the following link.

Prevention Committee awards

Dr. Murat Gultekin was awarded the IGCS Distinguished Advocacy Award for his extensive and tireless efforts to unify advocacy NGOs throughout Europe, forming ENGAGe. As the leading founder of HPV DNA Screening, Mobile Trucks and Central Mammography Report Unit, cancer registry systems and community- based palliative care system he is partly responsible for major innovations in cancer screening in Turkey and around the world. For more info visit the IGCS website.